DOCETAXEL
Docegen-20

DOCEGEN-20 is indicated for the treatment of breast cancer (as adjuvant therapy in combination with doxorubicin and cyclophosphamide for operable node-positive or eligible node-negative disease; in combination with doxorubicin for locally advanced or metastatic disease; as monotherapy after failure of cytotoxic therapy; in combination with trastuzumab for HER2-overexpressing metastatic disease; and in combination with capecitabine after failure of prior chemotherapy), non-small cell lung cancer (as monotherapy after failure of prior chemotherapy or in combination with cisplatin for unresectable, locally advanced or metastatic disease), hormone-refractory metastatic prostate cancer (in combination with prednisone or prednisolone), metastatic gastric adenocarcinoma including gastroesophageal junction tumors (in combination with cisplatin and 5-fluorouracil), and locally advanced squamous cell carcinoma of the head and neck (as induction therapy in combination with cisplatin and 5-fluorouracil).

Packaging: Single vial
Shelf Life: 24 months
Origin: India
Dosage Form: Solution for IV Infusion